Serious adverse outcomes are categorized according to FDA-defined criteria, including: mortality (DE), life-threatening conditions (LT), hospitalization (HO), disability (DS), congenital anomalies (CA), and other medically significant events (OT)
Semaglutide is an FDA-approved medication originally developed for type 2 diabetes that has been shown to support significant, sustainable weight loss
The founder, Chris Spears, started the company after his own successful tirzepatide weight-loss journey
CJC-1295 No DAC (Modified GRF 1-29) is a short-acting GHRH analog studied for its role in stimulating pulsatile growth hormone release
Ideal candidates are motivated, open to lifestyle changes, and willing to follow a structured plan.
Central nervous system effects GLP-1 receptors are present in areas of the brain that control appetite and nausea, including the area postrema (the brain's 'vomiting centre')